Dr. Rahul P. Sharma, MBBS, FRACP is the Director of Structural Interventions at Stanford Healthcare, Associate Director of the Cardiac Catheterization Laboratory and Clinical Associate Professor of Medicine at Stanford University. Dr Sharma graduated from Monash University and completed his medicine and cardiology training at the Alfred Hospital in Melbourne, Australia. He completed an advanced interventional and structural fellowship at Cedars Sinai Medical Center in Los Angeles, California before joining Cedars Sinai as Clinical Faculty, Director of the Structural Imaging Core Laboratory and Associate Director of Interventional Cardiology Research. He was recruited to the role of Director of Structural Interventions at Stanford Healthcare in 2019.

Dr. Sharma is an Interventional Cardiologist with specialized clinical and research interests in structural heart disease, particularly transcatheter valve therapy and the application of artificial intelligence to healthcare. He has a large volume of expertise in transcatheter aortic, mitral and tricuspid replacement and repair, left atrial appendage occlusion, PFO/ASD/VSD closure, alcohol septal ablation and cerebral protection. He also has expertise in intracardiac echocardiography for structural heart disease. He is a clinical investigator in ongoing national multi-center research studies and clinical trials and has co-authored numerous peer reviewed, scientific articles and book chapters. Dr Sharma serves as a national and international clinical proctor for transcatheter procedures and is regularly invited to speak at major national and international scientific meetings. Dr Sharma sits on a number of scientific advisory boards and clinical society committees and is deeply committed to the training and education of the next generation of clinicians.

Dr. Sharma is the cofounder of Synchron, creator of the world’s first percutaneous brain computer interface. He has strong ties to large medical device strategics, works closely with startups and incubators and advises private equity and venture capital firms with an interest in healthcare.